Soluble CTLA4 mutant molecules and uses thereof

Details for Australian Patent Application No. 2001263466 (hide)

International Classifications

Event Publications

27 April 2006 Application Accepted

Published as AU-B-2001263466

15 June 2006 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 25 May 2006. Address for service in Australia - Phillips Ormonde & Fitzpatrick Level 21 367 Collins Street Melbourne VIC 3000

24 August 2006 Standard Patent Sealed

26 October 2006 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 25 May 2006

10 May 2012 Extension of Term of Standard Patents

Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 15 Mar 2012 For the goods NULOJIX belatacept (rch)

7 June 2012 Extension of Term of Standard Patents

Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 15 Mar 2012 For the goods NULOJIX belatacept (rch) Address for service in Australia: Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

25 October 2012 Extension granted

Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 15 Mar 2012 For the goods NULOJIX belatacept (rch) Extension of Term of patent pursuant to Section 77 expires on 23 May 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.